Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Shanghai Genemagic Biosciences Co. Ltd. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions involve 3 distinct examiners and are distributed across 2 distinct art units. WORSHAM, JESSICA N is the busiest examiner for the company, with 1 pending office action.
The presence of 3 pending office actions handled by 3 distinct examiners means that no single examiner is managing more than one case. However, the concentration in 2 distinct art units indicates some overlap in the technical categories of the applications. This portfolio structure requires navigating the specific requirements of 2 different art units while coordinating with 3 separate examiners. The company must maintain consistency in its Biotechnology & Pharmaceuticals arguments across these 2 distinct art units. WORSHAM, JESSICA N is responsible for 1 pending office action out of the 3 total.
Practitioners should observe that the 3 distinct examiners will each provide an independent review of the claims. While the 2 distinct art units provide some technical focus, the company still faces three different examination styles. Successfully resolving the 3 pending office actions will require a coordinated effort across the 2 distinct art units. This distribution suggests a moderately diverse set of biological innovations currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.3% | +56.3% |
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717671 | NON-CODING RNA-MEDIATED NEUROLOGICAL DISEASE TREATMENT | WORSHAM, JESSICA N | — |
| 18697216 | DIRECT TRANSDIFFERENTIATION FOR TREATMENT OF NEUROLOGICAL DISEASE | LARA, CAROLINE MONSERRAT | — |
| 18259090 | TREATMENT OF NEUROLOGICAL DISEASES | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717671 | NON-CODING RNA-MEDIATED NEUROLOGICAL DISEASE TREATMENT | WORSHAM, JESSICA N | — |
| 18259090 | TREATMENT OF NEUROLOGICAL DISEASES | QIAN, CELINE X | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717671 | NON-CODING RNA-MEDIATED NEUROLOGICAL DISEASE TREATMENT | WORSHAM, JESSICA N | 1615 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18697216 | DIRECT TRANSDIFFERENTIATION FOR TREATMENT OF NEUROLOGICAL DISEASE | LARA, CAROLINE MONSERRAT | 1633 | §102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18259090 | TREATMENT OF NEUROLOGICAL DISEASES | QIAN, CELINE X | — | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial